A biotech company called Voyager Therapeutics now thinks it can extend the effects of L-Dopa by using a surprising approach: gene therapy.
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
R&D success and M&A activity loom as large swing factors for the bio sector in 2017 with the regulatory arena potentially at its most amenable for years.
Nearly two decades ago, the promise of precision medicine began making its mark on the pages of medical journals – along with speculation that “therapy with the right drug at the right dose in the right patient” – would define the future of medical treatment.
There was a significant drop-off in NME approvals by FDA in 2016, but there were not enough new drug applications with user fee goals to reach the lofty 2015 total.
International private equity firm Cinven announced a deal to acquire Bioclinica, a global provider of clinical trial services and technology to contract research organizations and pharmaceutical companies, from Water Street Healthcare Partners and JLL Partners.
Privately held DS Biopharma is spinning out a new company called Afimmune that is focused solely on fibrotic conditions such as NASH and pulmonary disorders including COPD and IPF.
Auris Medical Holding AG said its experimental drug for acute inner ear tinnitus missed the main goals of a late-stage study.
OncoGenex is exploring strategic alternatives after its experimental drug failed to show survival benefit in a late-stage study for advanced prostate cancer.
Vertex Pharmaceuticals Inc. announced it terminated clinical development of one late-stage trial studying the combination of its investigational cystic fibrosis compound VX-661 with the approved cystic fibrosis drug Kalydeco.
Women who take the pain reliever acetaminophen during pregnancy may be more likely to have children with behavior problems than those who do not.
For obese people who sit for most of the day, replacing some sitting time with standing, slow walking or slow cycling reduces average blood sugar across the day.
The HHS has shifted $81 million in funds from other projects to continue work on developing vaccines to fight Zika in the absence of any funding from U.S. lawmakers.
Paraplegic patients recovered partial limb control and feeling after using brain-machine interface technologies.
AstraZeneca has invested another $140 million in Moderna Therapeutics’ drugs based on a molecule known as messenger RNA.
Eli Lilly’s late-stage trial of its experimental breast cancer combination drug will continue even though it failed to meet its interim effectiveness goal.
Japan’s Eisai Co. said the U.S. FDA had confirmed that there was sufficient data to start Phase III studies of a drug it is co-developing to treat early Alzheimer’s disease.
AstraZeneca’s cancer drug pipeline suffered a setback when the experimental drug selumetinib failed to meet its goal in a late-stage trial for lung cancer.
Mesoblast Ltd. said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines.
Scientists have found a single class of drugs that can kill the parasites responsible for three tropical diseases that affect millions in Africa, Asia and Latin America.
Helsinn Group and MEI Pharma inked an exclusive licensing, development and commercialization deal to develop and market Pracinostat to treat AML.
The first new asthma pill in decades has produced promising results in a small study, potentially paving the way for another treatment option by the end of the decade.
Bristol-Myers Squibb’s blockbuster Opdivo failed to slow progression of symptoms in previously untreated patients with advanced lung cancer in a late-stage study.
Almost every reported concomitant medication has a reason – and many, if not all of these reasons should be reported as adverse events.